Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →More from Lucrin Depot
Other strengths and forms by Unimed Unihealth Pharmaceuticals Ltd.
Indications & Uses
Prostate Cancer Leuprorelin Acetate 3 Month 11.25 mg is indicated for the palliative treatment of advanced prostatic cancer. It gives another option when orchiectomy or estrogen administration is either not indicated or not acceptable to the patient. Endometriosis The 3 month 11.25 mg strength is indicated for treating endometriosis for a period of six months. You can use it as the only therapy, or as an adjunct to surgery. Uterine Fibroids It is also indicated for leiomyoma uteri (uterine fibroids), for a period up to six months. The therapy may be given before myomectomy or hysterectomy, or it may give symptomatic relief to a perimenopausal woman who does not want surgery. Breast Cancer Leuprorelin Acetate 3 month 11.25 mg is also indicated for treating breast cancer in pre- and peri-menopausal women in whom hormone therapy is specified.
Pharmacology
Leuprorelin acetate is a GnRH agonist. Given continuously and in therapeutic doses, it acts as a potent inhibitor of gonadotropin secretion. Animal and human studies show that after an initial stimulation, chronic administration of leuprorelin acetate results in suppression. Administration has also resulted in inhibition of the growth of certain hormone dependent tumors (prostatic tumors in Nobel and Dunning male rats, and DMBA-induced mammary tumors in female rats), as well as atrophy of the reproductive organs. In humans, the first effect is a rise in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH). This leads to a transient increase in the gonadal steroids (testosterone and dihydrotestosterone in males, and estrone and estradiol in pre-menopausal females). With continuous administration, however, the levels of LH, FSH and the sex steroids go down. In males, testosterone is reduced to castrate or prepubertal levels. In pre-menopausal females, estrogens are reduced to post-menopausal levels. These hormonal changes occur within a month of starting therapy at recommended doses.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Leuprorelin Acetate 3 Month 11.25 mg must be given under the supervision of a physician. Once reconstituted, the suspension should be discarded if it isn't used immediately. As with other injected medicines, the injection sites should be varied from time to time. Reconstitute the microspheres just before giving the injection. The dose of 3 Month 11.25 mg is a single subcutaneous or intramuscular injection every three months. For endometriosis, therapy should begin on the first day of the menstrual cycle, after pregnancy has been ruled out. Amenorrhea usually shows that the patient is responding clinically, although spotting or bleeding from the atrophic endometrium can still occur. For uterine fibroids, the recommended duration of therapy is up to 6 months.
Side Effects
These side effects are commonly linked to the pharmacological actions of Leuprorelin Acetate on steroidogenesis. In men, the following have been seen. Neoplasm benign, malignant and unspecified (including cysts and polyps): prostate tumor flare, aggravation of prostate cancer. Metabolism and nutrition disorders: weight gain, weight loss. Psychiatric disorders: loss or decreased libido, increase libido. Nervous system disorders: headache, muscular weakness. Vascular disorders: vasodilatation, hot flushes, hypotension, orthostatic hypotension. Skin and subcutaneous tissue disorders: dry skin, hyperhydrosis, rash, urticaria, hair growth abnormal, hair disorder, night sweats, hypotrichosis, pigmentation disorder, cold sweat, hirsutism. Reproductive system and breast disorders: gynaecomastia, breast tenderness, erectile dysfunction, testicular pain, breast enlargement, breast pain, prostate pain, penile swelling, penis disorder, testis atrophy. General disorders and administration site conditions: mucosal dryness. Investigations: PSA increased, bone density decreased. With long exposure (6 to 12 months): diabetes mellitus, glucose tolerance impaired, total cholesterol increased, LDL increased, triglycerides increased, osteoporosis. In women, the list is as follows. Metabolism and nutrition disorders: weight gain, weight loss. Psychiatric disorders: loss or decreased libido, increased libido, affects lability. Nervous system disorders: headache. Vascular disorders: hot flushes, vasodilatation, hypotension. Skin and subcutaneous tissue disorders: acne, seborrhea, dry skin, urticaria, skin odour abnormal, hyperhydrosis, hair growth abnormal, hirsutism, hair disorder, eczema, nail disorder, night sweats. Reproductive system and breast disorders: vaginal haemorrhage, dysmenorrhea, menstrual disorder, breast enlargement, breast engorgement, breast atrophy, genital discharge, vaginal discharge, galactorrhea, breast pain, metrorrhagia, menopausal symptoms, dyspareunia, uterine disorder, vaginitis, menorrhagia. General disorders and administration site conditions: feeling hot, irritability. Investigations: bone density decreased. With long exposure (6 to 12 months): diabetes mellitus, glucose tolerance impaired, total cholesterol increased, LDL increased, triglycerides increased, osteoporosis.
Cautions & Contraindications
Warnings & Precautions
All Populations The effect of Leuprorelin Acetate for Depot Suspension 3 Month 11.25 mg lasts throughout the course of therapy, so the medicine should only be used in patients who need hormonal suppression for at least three months. In the early phase of treatment, gonadotropins and sex steroids rise above baseline because of the natural stimulatory effect of the drug. Because of this, clinical signs and symptoms may increase. Existing signs and symptoms may get worse during the first weeks of treatment, and this worsening may contribute to paralysis, with or without fatal complications. Bone Mineral Density Bone mineral density can change during any hypoestrogenic state in women, and with long-term use in men with prostate cancer. There is no data in men on whether this reverses after Leuprorelin Acetate is stopped. In women, the loss of bone mineral density may be reversible after withdrawal of Leuprorelin Acetate. Convulsions Convulsions have been reported after marketing in patients taking Leuprorelin Acetate. These patients included women and children, patients with a history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies or tumors, and patients taking other medicines linked with convulsions, such as bupropion and SSRIs. Convulsions have also been reported in patients who had none of these conditions.
Contraindications
Leuprorelin Acetate 3 Month 11.25 mg must not be used in patients who are known to be hypersensitive to leuprorelin acetate, similar nonapeptides, or any of the excipients. Isolated cases of anaphylaxis have been reported with the monthly formulation of Leuprorelin Acetate for Depot Suspension. The 3 Month 11.25 mg product is also not suitable for treating patients after an orchiectomy. It must not be used when there is undiagnosed abnormal vaginal bleeding either. It is contraindicated in women who are pregnant or may become pregnant while receiving the drug. Similar studies in rats failed to show an increase in fetal malformations. In rabbits, the two higher doses of leuprorelin acetate caused increased fetal mortality and decreased fetal weights, and in rats the highest dose did the same. These effects on fetal mortality are logical consequences of the changes in hormone levels that this drug brings about. So fetal abnormalities and spontaneous abortion may occur if the drug is given during pregnancy.
Pregnancy & Breastfeeding
Nobody knows yet whether leuprorelin acetate passes into human breast milk. Because of this, nursing mothers should not use leuprorelin acetate.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Special populations: how Leuprorelin Acetate behaves in the body has not been determined in patients with impaired liver function or impaired kidney function.
Storage
Leuprorelin Acetate has a shelf life of 36 months if the pack is unopened. Don't store it above 25°C, and don't let it freeze. Once it has been mixed with the sterile diluent, give the suspension straight away.
Common questions about Lucrin Depot 3.75 mg
What is Lucrin Depot 3.75 mg IM/SC Injection?
Lucrin Depot 3.75 mg IM/SC Injection is a medicine that contains Leuprorelin Acetate. It is made by Unimed Unihealth Pharmaceuticals Ltd. It belongs to the Drugs acting on the Uterus group of medicines.
What is Lucrin Depot used for?
Prostate Cancer Leuprorelin Acetate 3 Month 11.25 mg is indicated for the palliative treatment of advanced prostatic cancer. It gives another option when orchiectomy or estrogen administration is either not indicated or not acceptable to the patient.
What are the side effects of Lucrin Depot?
These side effects are commonly linked to the pharmacological actions of Leuprorelin Acetate on steroidogenesis. In men, the following have been seen.
Can I take Lucrin Depot during pregnancy or while breastfeeding?
Nobody knows yet whether leuprorelin acetate passes into human breast milk. Because of this, nursing mothers should not use leuprorelin acetate. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Lucrin Depot?
Leuprorelin Acetate has a shelf life of 36 months if the pack is unopened. Don't store it above 25°C, and don't let it freeze.
Do I need a prescription for Lucrin Depot?
Lucrin Depot is a prescription (Rx) medicine. Take it as your doctor advises.